Eli Lilly, Merck, and Pfizer are major players in the pharmaceutical industry, with Lilly leading in diabetes and weight management and the others excelling in oncology. However, Moderna has outperformed them this year, seeing a 43% rise in share value, driven by promising advancements in its vaccine pipeline. Notably, Moderna’s mRNA-1010 flu vaccine has shown effectiveness against traditional vaccines, and its mRNA-4157 cancer vaccine, in collaboration with Merck, could significantly impact melanoma treatment. Despite potential, investors face risks regarding Moderna’s profitability and the volatility of its stock, suggesting cautious investment for those interested in this biotech firm.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/investing/2026/06/03/meet-the-biotech-stock-thats-trouncing-lilly-merck/
